Trove
Sign In Sign Up

Mr. Menendez

Person
Mentions
15
Relationships
2
Events
0
Documents
4
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.
2 total relationships
Connected Entity Relationship Type
Strength (mentions)
Documents Actions
person Mr. Hugin
Unknown
6
1
View
person Mr. Hugin
Political opponents
5
1
View
No events found for this entity.

HOUSE_OVERSIGHT_028421.jpg

This document contains text segments describing the pharmaceutical company Celgene, its former executive Mr. Hugin, and its practice of raising drug prices. Specifically, it details price hikes for the drug Revlimid, the financial impact on the company, and the human cost as exemplified by a patient, Elaine Kodish. The text also includes commentary from a financial analyst and mentions a political campaign leveraging the issue.

Data snippet containing article text
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_028420.jpg

The document is JSON code describing an article about the pharmaceutical company Celgene. The article alleges that Celgene used a federal safety program (REMS) to block generic competition for its drugs, Revlimid and Thalomid, leading to lawsuits from companies like Mylan. The text also mentions a patient paying high costs and a professor criticizing Celgene's actions.

Document metadata in json format
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_028417.jpg

This document is a data extract, likely from a news article, which has been marked as an exhibit for a House Oversight investigation. The text details the history of the pharmaceutical company Celgene and its drug Thalomid (thalidomide), including its approval by the F.D.A. in 1998 and the context of executive Bob Hugin's subsequent political career. The document contains no information related to Jeffrey Epstein or his associates.

Data extract from a news article, identified as exhibit 'house oversight 028417'.
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_028416.jpg

This document is an excerpt from an article detailing controversies surrounding pharmaceutical executive Mr. Hugin, a former CEO of Celgene. It highlights Celgene's aggressive drug promotion, a $280 million settlement for illegal marketing, and accusations of fighting generic competition. The text notes that these issues, particularly rising drug costs, are being used against Hugin in a political campaign by his opponent, Mr. Menendez.

News article excerpt / document for review
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search